ERG and prostate carcinoma: FZD8 is directly targeted and activated by ERG, which is involved in bone metastasis of prostate cancer by regulating Wnt-11 and TGF-β signaling to stimulate epithelial–mesenchymal transition in prostate cancer [11,12].